nodes	percent_of_prediction	percent_of_DWPC	metapath
Medroxyprogesterone Acetate—Talipes—Riluzole—amyotrophic lateral sclerosis	0.0778	0.116	CcSEcCtD
Medroxyprogesterone Acetate—Uterine leiomyoma—Riluzole—amyotrophic lateral sclerosis	0.018	0.0268	CcSEcCtD
Medroxyprogesterone Acetate—Salivary gland enlargement—Riluzole—amyotrophic lateral sclerosis	0.0169	0.0252	CcSEcCtD
Medroxyprogesterone Acetate—SHBG—hindlimb—amyotrophic lateral sclerosis	0.0159	0.129	CbGeAlD
Medroxyprogesterone Acetate—Facial paralysis—Riluzole—amyotrophic lateral sclerosis	0.0147	0.022	CcSEcCtD
Medroxyprogesterone Acetate—Osteonecrosis—Riluzole—amyotrophic lateral sclerosis	0.0126	0.0188	CcSEcCtD
Medroxyprogesterone Acetate—VIIth nerve paralysis—Riluzole—amyotrophic lateral sclerosis	0.0114	0.0171	CcSEcCtD
Medroxyprogesterone Acetate—Pericarditis—Riluzole—amyotrophic lateral sclerosis	0.0108	0.0162	CcSEcCtD
Medroxyprogesterone Acetate—Cerebral ischaemia—Riluzole—amyotrophic lateral sclerosis	0.0097	0.0145	CcSEcCtD
Medroxyprogesterone Acetate—Vaginal moniliasis—Riluzole—amyotrophic lateral sclerosis	0.00929	0.0139	CcSEcCtD
Medroxyprogesterone Acetate—Vulvovaginal candidiasis—Riluzole—amyotrophic lateral sclerosis	0.00891	0.0133	CcSEcCtD
Medroxyprogesterone Acetate—Vulvovaginal mycotic infection—Riluzole—amyotrophic lateral sclerosis	0.00857	0.0128	CcSEcCtD
Medroxyprogesterone Acetate—Cerebral haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00846	0.0126	CcSEcCtD
Medroxyprogesterone Acetate—Osteoporosis—Riluzole—amyotrophic lateral sclerosis	0.00836	0.0125	CcSEcCtD
Medroxyprogesterone Acetate—Myoclonus—Riluzole—amyotrophic lateral sclerosis	0.00779	0.0116	CcSEcCtD
Medroxyprogesterone Acetate—Polyp—Riluzole—amyotrophic lateral sclerosis	0.0077	0.0115	CcSEcCtD
Medroxyprogesterone Acetate—Libido increased—Riluzole—amyotrophic lateral sclerosis	0.0077	0.0115	CcSEcCtD
Medroxyprogesterone Acetate—Embolism—Riluzole—amyotrophic lateral sclerosis	0.0073	0.0109	CcSEcCtD
Medroxyprogesterone Acetate—SHBG—hindbrain—amyotrophic lateral sclerosis	0.00723	0.0586	CbGeAlD
Medroxyprogesterone Acetate—Supraventricular tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00715	0.0107	CcSEcCtD
Medroxyprogesterone Acetate—Cyst—Riluzole—amyotrophic lateral sclerosis	0.00701	0.0105	CcSEcCtD
Medroxyprogesterone Acetate—Paranoia—Riluzole—amyotrophic lateral sclerosis	0.00688	0.0103	CcSEcCtD
Medroxyprogesterone Acetate—HSD3B2—nervous system—amyotrophic lateral sclerosis	0.00684	0.0555	CbGeAlD
Medroxyprogesterone Acetate—Hypercalcaemia—Riluzole—amyotrophic lateral sclerosis	0.00675	0.0101	CcSEcCtD
Medroxyprogesterone Acetate—Thrombosis—Riluzole—amyotrophic lateral sclerosis	0.00662	0.00989	CcSEcCtD
Medroxyprogesterone Acetate—HSD3B2—central nervous system—amyotrophic lateral sclerosis	0.00659	0.0534	CbGeAlD
Medroxyprogesterone Acetate—Metrorrhagia—Riluzole—amyotrophic lateral sclerosis	0.00656	0.0098	CcSEcCtD
Medroxyprogesterone Acetate—PGR—hindbrain—amyotrophic lateral sclerosis	0.00651	0.0528	CbGeAlD
Medroxyprogesterone Acetate—Neuritis—Riluzole—amyotrophic lateral sclerosis	0.00628	0.00938	CcSEcCtD
Medroxyprogesterone Acetate—Abscess—Riluzole—amyotrophic lateral sclerosis	0.00592	0.00885	CcSEcCtD
Medroxyprogesterone Acetate—Nephrolithiasis—Riluzole—amyotrophic lateral sclerosis	0.00583	0.00871	CcSEcCtD
Medroxyprogesterone Acetate—Glycosuria—Riluzole—amyotrophic lateral sclerosis	0.00578	0.00864	CcSEcCtD
Medroxyprogesterone Acetate—Endocrine disorder—Riluzole—amyotrophic lateral sclerosis	0.00565	0.00844	CcSEcCtD
Medroxyprogesterone Acetate—Breast pain—Riluzole—amyotrophic lateral sclerosis	0.00537	0.00802	CcSEcCtD
Medroxyprogesterone Acetate—Amenorrhoea—Riluzole—amyotrophic lateral sclerosis	0.00533	0.00797	CcSEcCtD
Medroxyprogesterone Acetate—HSD3B2—brain—amyotrophic lateral sclerosis	0.00523	0.0424	CbGeAlD
Medroxyprogesterone Acetate—Bone disorder—Riluzole—amyotrophic lateral sclerosis	0.00519	0.00775	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—hindbrain—amyotrophic lateral sclerosis	0.00509	0.0413	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—nerve—amyotrophic lateral sclerosis	0.00502	0.0407	CbGeAlD
Medroxyprogesterone Acetate—Leukocytosis—Riluzole—amyotrophic lateral sclerosis	0.00499	0.00745	CcSEcCtD
Medroxyprogesterone Acetate—Ulcer—Riluzole—amyotrophic lateral sclerosis	0.00495	0.0074	CcSEcCtD
Medroxyprogesterone Acetate—Dysarthria—Riluzole—amyotrophic lateral sclerosis	0.00495	0.0074	CcSEcCtD
Medroxyprogesterone Acetate—Phosphatase alkaline increased—Riluzole—amyotrophic lateral sclerosis	0.00469	0.007	CcSEcCtD
Medroxyprogesterone Acetate—Pulmonary embolism—Riluzole—amyotrophic lateral sclerosis	0.00469	0.007	CcSEcCtD
Medroxyprogesterone Acetate—Hepatocellular injury—Riluzole—amyotrophic lateral sclerosis	0.00469	0.007	CcSEcCtD
Medroxyprogesterone Acetate—Injection site reaction—Riluzole—amyotrophic lateral sclerosis	0.00466	0.00696	CcSEcCtD
Medroxyprogesterone Acetate—Fluid retention—Riluzole—amyotrophic lateral sclerosis	0.00445	0.00665	CcSEcCtD
Medroxyprogesterone Acetate—Cramps of lower extremities—Riluzole—amyotrophic lateral sclerosis	0.00431	0.00643	CcSEcCtD
Medroxyprogesterone Acetate—Neoplasm—Riluzole—amyotrophic lateral sclerosis	0.00424	0.00633	CcSEcCtD
Medroxyprogesterone Acetate—SHBG—brainstem—amyotrophic lateral sclerosis	0.00414	0.0336	CbGeAlD
Medroxyprogesterone Acetate—Sepsis—Riluzole—amyotrophic lateral sclerosis	0.00407	0.00607	CcSEcCtD
Medroxyprogesterone Acetate—Euphoric mood—Riluzole—amyotrophic lateral sclerosis	0.00403	0.00601	CcSEcCtD
Medroxyprogesterone Acetate—Diabetes mellitus—Riluzole—amyotrophic lateral sclerosis	0.00391	0.00584	CcSEcCtD
Medroxyprogesterone Acetate—Blood alkaline phosphatase increased—Riluzole—amyotrophic lateral sclerosis	0.00391	0.00584	CcSEcCtD
Medroxyprogesterone Acetate—Hepatic function abnormal—Riluzole—amyotrophic lateral sclerosis	0.00389	0.00581	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—medulla oblongata—amyotrophic lateral sclerosis	0.00384	0.0311	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—hindbrain—amyotrophic lateral sclerosis	0.00376	0.0305	CbGeAlD
Medroxyprogesterone Acetate—Cardiac failure congestive—Riluzole—amyotrophic lateral sclerosis	0.00375	0.0056	CcSEcCtD
Medroxyprogesterone Acetate—Libido decreased—Riluzole—amyotrophic lateral sclerosis	0.00367	0.00548	CcSEcCtD
Medroxyprogesterone Acetate—Increased appetite—Riluzole—amyotrophic lateral sclerosis	0.00362	0.00541	CcSEcCtD
Medroxyprogesterone Acetate—Amnesia—Riluzole—amyotrophic lateral sclerosis	0.00362	0.00541	CcSEcCtD
Medroxyprogesterone Acetate—Thirst—Riluzole—amyotrophic lateral sclerosis	0.00357	0.00534	CcSEcCtD
Medroxyprogesterone Acetate—Purpura—Riluzole—amyotrophic lateral sclerosis	0.00353	0.00527	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactoid reaction—Riluzole—amyotrophic lateral sclerosis	0.00351	0.00525	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—spinal cord—amyotrophic lateral sclerosis	0.00343	0.0278	CbGeAlD
Medroxyprogesterone Acetate—Osteoarthritis—Riluzole—amyotrophic lateral sclerosis	0.0034	0.00508	CcSEcCtD
Medroxyprogesterone Acetate—Disturbance in sexual arousal—Riluzole—amyotrophic lateral sclerosis	0.00338	0.00504	CcSEcCtD
Medroxyprogesterone Acetate—Affect lability—Riluzole—amyotrophic lateral sclerosis	0.00335	0.005	CcSEcCtD
Medroxyprogesterone Acetate—Migraine—Riluzole—amyotrophic lateral sclerosis	0.00335	0.005	CcSEcCtD
Medroxyprogesterone Acetate—Psychotic disorder—Riluzole—amyotrophic lateral sclerosis	0.00332	0.00496	CcSEcCtD
Medroxyprogesterone Acetate—Face oedema—Riluzole—amyotrophic lateral sclerosis	0.00328	0.00491	CcSEcCtD
Medroxyprogesterone Acetate—Urinary retention—Riluzole—amyotrophic lateral sclerosis	0.00323	0.00483	CcSEcCtD
Medroxyprogesterone Acetate—Mood swings—Riluzole—amyotrophic lateral sclerosis	0.00322	0.00481	CcSEcCtD
Medroxyprogesterone Acetate—Ataxia—Riluzole—amyotrophic lateral sclerosis	0.0032	0.00478	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—embryo—amyotrophic lateral sclerosis	0.00318	0.0258	CbGeAlD
Medroxyprogesterone Acetate—Orthostatic hypotension—Riluzole—amyotrophic lateral sclerosis	0.00311	0.00464	CcSEcCtD
Medroxyprogesterone Acetate—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.0031	0.00462	CcSEcCtD
Medroxyprogesterone Acetate—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.00307	0.00459	CcSEcCtD
Medroxyprogesterone Acetate—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.003	0.00448	CcSEcCtD
Medroxyprogesterone Acetate—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.003	0.00448	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.00296	0.00442	CcSEcCtD
Medroxyprogesterone Acetate—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.00294	0.00439	CcSEcCtD
Medroxyprogesterone Acetate—Asthma—Riluzole—amyotrophic lateral sclerosis	0.00294	0.00439	CcSEcCtD
Medroxyprogesterone Acetate—Influenza—Riluzole—amyotrophic lateral sclerosis	0.00294	0.00439	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—brainstem—amyotrophic lateral sclerosis	0.00292	0.0237	CbGeAlD
Medroxyprogesterone Acetate—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.00283	0.00422	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00282	0.00421	CcSEcCtD
Medroxyprogesterone Acetate—Dysuria—Riluzole—amyotrophic lateral sclerosis	0.00275	0.00411	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—cerebellum—amyotrophic lateral sclerosis	0.00272	0.022	CbGeAlD
Medroxyprogesterone Acetate—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.00272	0.00406	CcSEcCtD
Medroxyprogesterone Acetate—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.00268	0.004	CcSEcCtD
Medroxyprogesterone Acetate—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00266	0.00397	CcSEcCtD
Medroxyprogesterone Acetate—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00262	0.00392	CcSEcCtD
Medroxyprogesterone Acetate—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00262	0.00392	CcSEcCtD
Medroxyprogesterone Acetate—Depression—Riluzole—amyotrophic lateral sclerosis	0.00261	0.0039	CcSEcCtD
Medroxyprogesterone Acetate—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.00258	0.00386	CcSEcCtD
Medroxyprogesterone Acetate—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.00257	0.00384	CcSEcCtD
Medroxyprogesterone Acetate—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.00257	0.00384	CcSEcCtD
Medroxyprogesterone Acetate—Jaundice—Riluzole—amyotrophic lateral sclerosis	0.00256	0.00382	CcSEcCtD
Medroxyprogesterone Acetate—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.00256	0.00382	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.00255	0.00381	CcSEcCtD
Medroxyprogesterone Acetate—Sweating—Riluzole—amyotrophic lateral sclerosis	0.00251	0.00375	CcSEcCtD
Medroxyprogesterone Acetate—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00248	0.0037	CcSEcCtD
Medroxyprogesterone Acetate—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.00247	0.00369	CcSEcCtD
Medroxyprogesterone Acetate—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.00246	0.00367	CcSEcCtD
Medroxyprogesterone Acetate—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.0024	0.00358	CcSEcCtD
Medroxyprogesterone Acetate—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.00237	0.00353	CcSEcCtD
Medroxyprogesterone Acetate—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.00235	0.00352	CcSEcCtD
Medroxyprogesterone Acetate—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00235	0.00352	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—embryo—amyotrophic lateral sclerosis	0.00235	0.019	CbGeAlD
Medroxyprogesterone Acetate—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.00234	0.00349	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00232	0.00347	CcSEcCtD
Medroxyprogesterone Acetate—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.00232	0.00346	CcSEcCtD
Medroxyprogesterone Acetate—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.00231	0.00345	CcSEcCtD
Medroxyprogesterone Acetate—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00231	0.00345	CcSEcCtD
Medroxyprogesterone Acetate—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.00223	0.00332	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—brain—amyotrophic lateral sclerosis	0.00221	0.0179	CbGeAlD
Medroxyprogesterone Acetate—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.0022	0.00329	CcSEcCtD
Medroxyprogesterone Acetate—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00218	0.00326	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—brainstem—amyotrophic lateral sclerosis	0.00215	0.0175	CbGeAlD
Medroxyprogesterone Acetate—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00214	0.00319	CcSEcCtD
Medroxyprogesterone Acetate—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.00213	0.00318	CcSEcCtD
Medroxyprogesterone Acetate—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00212	0.00317	CcSEcCtD
Medroxyprogesterone Acetate—Chills—Riluzole—amyotrophic lateral sclerosis	0.00211	0.00315	CcSEcCtD
Medroxyprogesterone Acetate—SHBG—central nervous system—amyotrophic lateral sclerosis	0.00209	0.0169	CbGeAlD
Medroxyprogesterone Acetate—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.00208	0.00311	CcSEcCtD
Medroxyprogesterone Acetate—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.00206	0.00308	CcSEcCtD
Medroxyprogesterone Acetate—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00205	0.00306	CcSEcCtD
Medroxyprogesterone Acetate—SHBG—cerebellum—amyotrophic lateral sclerosis	0.00204	0.0166	CbGeAlD
Medroxyprogesterone Acetate—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.00202	0.00302	CcSEcCtD
Medroxyprogesterone Acetate—Tension—Riluzole—amyotrophic lateral sclerosis	0.00201	0.003	CcSEcCtD
Medroxyprogesterone Acetate—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.00201	0.003	CcSEcCtD
Medroxyprogesterone Acetate—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.00199	0.00297	CcSEcCtD
Medroxyprogesterone Acetate—Back pain—Riluzole—amyotrophic lateral sclerosis	0.00198	0.00296	CcSEcCtD
Medroxyprogesterone Acetate—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.00197	0.00294	CcSEcCtD
Medroxyprogesterone Acetate—PGR—nervous system—amyotrophic lateral sclerosis	0.00195	0.0158	CbGeAlD
Medroxyprogesterone Acetate—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00192	0.00287	CcSEcCtD
Medroxyprogesterone Acetate—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.0019	0.00284	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.00189	0.00283	CcSEcCtD
Medroxyprogesterone Acetate—Agitation—Riluzole—amyotrophic lateral sclerosis	0.00188	0.00281	CcSEcCtD
Medroxyprogesterone Acetate—PGR—central nervous system—amyotrophic lateral sclerosis	0.00188	0.0153	CbGeAlD
Medroxyprogesterone Acetate—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.00187	0.0028	CcSEcCtD
Medroxyprogesterone Acetate—AR—spinal cord—amyotrophic lateral sclerosis	0.00185	0.015	CbGeAlD
Medroxyprogesterone Acetate—Malaise—Riluzole—amyotrophic lateral sclerosis	0.00185	0.00276	CcSEcCtD
Medroxyprogesterone Acetate—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.00184	0.00275	CcSEcCtD
Medroxyprogesterone Acetate—PGR—cerebellum—amyotrophic lateral sclerosis	0.00184	0.0149	CbGeAlD
Medroxyprogesterone Acetate—Syncope—Riluzole—amyotrophic lateral sclerosis	0.00184	0.00274	CcSEcCtD
Medroxyprogesterone Acetate—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.00181	0.0027	CcSEcCtD
Medroxyprogesterone Acetate—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.0018	0.00269	CcSEcCtD
Medroxyprogesterone Acetate—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.00178	0.00265	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.00174	0.00261	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.00174	0.00261	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.00174	0.00261	CcSEcCtD
Medroxyprogesterone Acetate—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00174	0.0026	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00173	0.00259	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.00172	0.00257	CcSEcCtD
Medroxyprogesterone Acetate—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.00171	0.00255	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.00169	0.00252	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.00167	0.0025	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Riluzole—amyotrophic lateral sclerosis	0.00167	0.0025	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Riluzole—amyotrophic lateral sclerosis	0.00166	0.00248	CcSEcCtD
Medroxyprogesterone Acetate—SHBG—brain—amyotrophic lateral sclerosis	0.00166	0.0134	CbGeAlD
Medroxyprogesterone Acetate—Shock—Riluzole—amyotrophic lateral sclerosis	0.00165	0.00246	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00164	0.00245	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00164	0.00245	CcSEcCtD
Medroxyprogesterone Acetate—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00163	0.00244	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00162	0.00243	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.00162	0.00241	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.00159	0.00238	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.00156	0.00233	CcSEcCtD
Medroxyprogesterone Acetate—AR—nervous system—amyotrophic lateral sclerosis	0.00156	0.0126	CbGeAlD
Medroxyprogesterone Acetate—ESR1—nervous system—amyotrophic lateral sclerosis	0.00153	0.0124	CbGeAlD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00152	0.00228	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.00151	0.00226	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.0015	0.00224	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—medulla oblongata—amyotrophic lateral sclerosis	0.0015	0.0122	CbGeAlD
Medroxyprogesterone Acetate—AR—central nervous system—amyotrophic lateral sclerosis	0.0015	0.0122	CbGeAlD
Medroxyprogesterone Acetate—PGR—brain—amyotrophic lateral sclerosis	0.00149	0.0121	CbGeAlD
Medroxyprogesterone Acetate—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.00149	0.00223	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.00149	0.00222	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—central nervous system—amyotrophic lateral sclerosis	0.00147	0.0119	CbGeAlD
Medroxyprogesterone Acetate—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.00147	0.0022	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.00145	0.00217	CcSEcCtD
Medroxyprogesterone Acetate—Progesterone—SIGMAR1—amyotrophic lateral sclerosis	0.00145	0.722	CrCbGaD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00144	0.00216	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00144	0.00215	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—cerebellum—amyotrophic lateral sclerosis	0.00144	0.0117	CbGeAlD
Medroxyprogesterone Acetate—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00143	0.00214	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.00138	0.00206	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00137	0.00204	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—spinal cord—amyotrophic lateral sclerosis	0.00134	0.0109	CbGeAlD
Medroxyprogesterone Acetate—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.00133	0.00198	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.00132	0.00197	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.00132	0.00197	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.00123	0.00184	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.0012	0.00179	CcSEcCtD
Medroxyprogesterone Acetate—AR—brain—amyotrophic lateral sclerosis	0.00119	0.00965	CbGeAlD
Medroxyprogesterone Acetate—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00118	0.00177	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—brain—amyotrophic lateral sclerosis	0.00117	0.00947	CbGeAlD
Medroxyprogesterone Acetate—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00114	0.00171	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—nervous system—amyotrophic lateral sclerosis	0.00113	0.00914	CbGeAlD
Medroxyprogesterone Acetate—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00111	0.00165	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—central nervous system—amyotrophic lateral sclerosis	0.00109	0.0088	CbGeAlD
Medroxyprogesterone Acetate—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00106	0.00159	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—cerebellum—amyotrophic lateral sclerosis	0.00106	0.0086	CbGeAlD
Medroxyprogesterone Acetate—Rash—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00157	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00157	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00156	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000993	0.00148	CcSEcCtD
Medroxyprogesterone Acetate—CYP2C8—brain—amyotrophic lateral sclerosis	0.000963	0.0078	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—brain—amyotrophic lateral sclerosis	0.000862	0.00699	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.000853	0.00692	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000821	0.00666	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—SIDS Susceptibility Pathways—SLC1A3—amyotrophic lateral sclerosis	0.00068	0.00331	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—SIDS Susceptibility Pathways—CHAT—amyotrophic lateral sclerosis	0.00068	0.00331	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—TPK1—amyotrophic lateral sclerosis	0.000678	0.00331	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Plasma membrane estrogen receptor signaling—IGF1—amyotrophic lateral sclerosis	0.000675	0.00329	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	0.000663	0.00323	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—SMN1—amyotrophic lateral sclerosis	0.000646	0.00315	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	0.000643	0.00314	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling mediated by p38-alpha and p38-beta—PTGS2—amyotrophic lateral sclerosis	0.000635	0.0031	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling by ERBB4—ERBB4—amyotrophic lateral sclerosis	0.000631	0.00308	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—PLB1—amyotrophic lateral sclerosis	0.00063	0.00307	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Generic Transcription Pathway—RARA—amyotrophic lateral sclerosis	0.000629	0.00306	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Validated nuclear estrogen receptor alpha network—C3—amyotrophic lateral sclerosis	0.000615	0.003	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	0.000605	0.00295	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—ATF1—amyotrophic lateral sclerosis	0.000593	0.00289	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—GSR—amyotrophic lateral sclerosis	0.000581	0.00283	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—ZNF470—amyotrophic lateral sclerosis	0.000579	0.00282	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—ZNF746—amyotrophic lateral sclerosis	0.000576	0.00281	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000568	0.00277	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000568	0.00277	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.000564	0.00275	CbGpPWpGaD
Medroxyprogesterone Acetate—Drospirenone—PTGS2—amyotrophic lateral sclerosis	0.000558	0.278	CrCbGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—VTA1—amyotrophic lateral sclerosis	0.000542	0.00264	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.00053	0.00258	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	0.00053	0.00258	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000519	0.00253	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000515	0.00251	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	0.000511	0.00249	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Aryl Hydrocarbon Receptor—PTGS2—amyotrophic lateral sclerosis	0.000511	0.00249	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	0.000496	0.00242	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—SMN1—amyotrophic lateral sclerosis	0.000492	0.0024	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Plasma membrane estrogen receptor signaling—MMP9—amyotrophic lateral sclerosis	0.000491	0.00239	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000483	0.00235	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Generic Transcription Pathway—RARA—amyotrophic lateral sclerosis	0.000479	0.00233	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000477	0.00233	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.000468	0.00228	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	0.000466	0.00227	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000466	0.00227	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	0.000464	0.00226	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—ATF1—amyotrophic lateral sclerosis	0.000457	0.00223	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000454	0.00221	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—ZNF470—amyotrophic lateral sclerosis	0.000446	0.00218	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—ZNF470—amyotrophic lateral sclerosis	0.000439	0.00214	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—ZNF746—amyotrophic lateral sclerosis	0.000439	0.00214	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	0.000436	0.00212	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.000435	0.00212	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—CASP9—amyotrophic lateral sclerosis	0.000433	0.00211	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000419	0.00204	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—CHMP2B—amyotrophic lateral sclerosis	0.000411	0.002	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—DAO—amyotrophic lateral sclerosis	0.000411	0.002	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	0.000402	0.00196	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—HNRNPA1—amyotrophic lateral sclerosis	0.000399	0.00195	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	0.000394	0.00192	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—SMN1—amyotrophic lateral sclerosis	0.000379	0.00185	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000379	0.00185	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling mediated by p38-alpha and p38-beta—TP53—amyotrophic lateral sclerosis	0.000378	0.00184	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	0.000376	0.00183	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—SMN1—amyotrophic lateral sclerosis	0.000374	0.00182	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—amyotrophic lateral sclerosis	0.000373	0.00182	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—PLB1—amyotrophic lateral sclerosis	0.000372	0.00181	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—FUS—amyotrophic lateral sclerosis	0.000371	0.00181	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—ERBB4—amyotrophic lateral sclerosis	0.00037	0.0018	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Generic Transcription Pathway—RARA—amyotrophic lateral sclerosis	0.000369	0.0018	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Generic Transcription Pathway—RARA—amyotrophic lateral sclerosis	0.000363	0.00177	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.00036	0.00176	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—EXOSC9—amyotrophic lateral sclerosis	0.00036	0.00175	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000359	0.00175	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	0.000352	0.00171	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—ZNF746—amyotrophic lateral sclerosis	0.000338	0.00165	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—ZNF746—amyotrophic lateral sclerosis	0.000333	0.00162	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—VCP—amyotrophic lateral sclerosis	0.000331	0.00161	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000328	0.0016	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—LKB1 signaling events—TP53—amyotrophic lateral sclerosis	0.000321	0.00156	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—AP-1 transcription factor network—MMP9—amyotrophic lateral sclerosis	0.00032	0.00156	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—AP-1 transcription factor network—MMP9—amyotrophic lateral sclerosis	0.000315	0.00154	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000311	0.00152	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000305	0.00149	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—HNRNPA1—amyotrophic lateral sclerosis	0.000304	0.00148	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	0.000304	0.00148	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—RARA—amyotrophic lateral sclerosis	0.000303	0.00148	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	0.000299	0.00146	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000292	0.00142	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	0.00029	0.00141	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	0.00029	0.00141	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—GSR—amyotrophic lateral sclerosis	0.000287	0.0014	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000287	0.0014	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—FUS—amyotrophic lateral sclerosis	0.000283	0.00138	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—EXOSC9—amyotrophic lateral sclerosis	0.000274	0.00134	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000267	0.0013	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Adipogenesis—IGF1—amyotrophic lateral sclerosis	0.000264	0.00129	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	0.000262	0.00127	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.00026	0.00127	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.000257	0.00125	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	0.000256	0.00125	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.00025	0.00122	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000248	0.00121	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000245	0.00119	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—CASP3—amyotrophic lateral sclerosis	0.000238	0.00116	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—CST3—amyotrophic lateral sclerosis	0.000238	0.00116	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	0.000236	0.00115	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000236	0.00115	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000236	0.00115	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—HNRNPA1—amyotrophic lateral sclerosis	0.000234	0.00114	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000233	0.00114	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000232	0.00113	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	0.000232	0.00113	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—HNRNPA1—amyotrophic lateral sclerosis	0.000231	0.00113	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—RARA—amyotrophic lateral sclerosis	0.000231	0.00112	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000225	0.00109	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—FUS—amyotrophic lateral sclerosis	0.000218	0.00106	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—AP-1 transcription factor network—TP53—amyotrophic lateral sclerosis	0.000217	0.00106	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	0.000215	0.00105	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—FUS—amyotrophic lateral sclerosis	0.000215	0.00105	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—AP-1 transcription factor network—TP53—amyotrophic lateral sclerosis	0.000214	0.00104	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	0.000212	0.00103	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—EXOSC9—amyotrophic lateral sclerosis	0.000211	0.00103	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000208	0.00102	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—EXOSC9—amyotrophic lateral sclerosis	0.000208	0.00101	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000206	0.001	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000205	0.001	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	0.000202	0.000983	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000199	0.000972	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000197	0.000961	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	0.000197	0.000961	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	0.000197	0.00096	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	0.000197	0.000958	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000196	0.000958	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—APOE—amyotrophic lateral sclerosis	0.000194	0.000946	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000193	0.000941	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Glucocorticoid receptor regulatory network—TP53—amyotrophic lateral sclerosis	0.000188	0.000919	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—CASP3—amyotrophic lateral sclerosis	0.000183	0.000893	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000183	0.000892	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—RARA—amyotrophic lateral sclerosis	0.000178	0.000866	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000177	0.000864	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	0.000176	0.000857	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—RARA—amyotrophic lateral sclerosis	0.000175	0.000853	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—CASP9—amyotrophic lateral sclerosis	0.000173	0.000842	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.00017	0.000827	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000167	0.000815	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	0.000167	0.000815	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	0.000163	0.000797	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.00016	0.000779	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—VAPB—amyotrophic lateral sclerosis	0.00016	0.000778	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—TPK1—amyotrophic lateral sclerosis	0.00016	0.000778	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000157	0.000767	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000156	0.000758	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	0.000155	0.000758	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—TP53—amyotrophic lateral sclerosis	0.000152	0.000743	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	0.000152	0.00074	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	0.000149	0.000727	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.000149	0.000726	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—ERBB4—amyotrophic lateral sclerosis	0.000148	0.000721	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	0.000147	0.000719	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000146	0.000712	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000136	0.000662	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000135	0.00066	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—PTGS2—amyotrophic lateral sclerosis	0.000133	0.000648	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—VAPB—amyotrophic lateral sclerosis	0.00013	0.000634	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—TPK1—amyotrophic lateral sclerosis	0.00013	0.000634	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	0.000129	0.000628	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000128	0.000622	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.000127	0.000619	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.000127	0.000618	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	0.000126	0.000616	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.000121	0.000591	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	0.000121	0.00059	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.00012	0.000587	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000119	0.000579	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—TP53—amyotrophic lateral sclerosis	0.000117	0.000572	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000116	0.000568	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—DAO—amyotrophic lateral sclerosis	0.000115	0.000563	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—APOE—amyotrophic lateral sclerosis	0.000114	0.000558	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000113	0.000552	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000112	0.000545	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000111	0.000539	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.00011	0.000538	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000107	0.000523	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000107	0.000521	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000104	0.000507	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000104	0.000506	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	0.000104	0.000505	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.0001	0.000489	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	9.74e-05	0.000475	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	9.73e-05	0.000474	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—APOE—amyotrophic lateral sclerosis	9.58e-05	0.000467	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	9.55e-05	0.000465	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—DAO—amyotrophic lateral sclerosis	9.4e-05	0.000458	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	9.23e-05	0.00045	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	9.13e-05	0.000445	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PLB1—amyotrophic lateral sclerosis	8.75e-05	0.000426	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—C3—amyotrophic lateral sclerosis	8.61e-05	0.00042	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	8.57e-05	0.000418	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	8.57e-05	0.000418	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	8.17e-05	0.000398	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—GSR—amyotrophic lateral sclerosis	8.07e-05	0.000394	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—APOE—amyotrophic lateral sclerosis	8.01e-05	0.000391	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—PTGS2—amyotrophic lateral sclerosis	7.84e-05	0.000382	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	7.84e-05	0.000382	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	7.68e-05	0.000375	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	7.35e-05	0.000358	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	7.29e-05	0.000355	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PLB1—amyotrophic lateral sclerosis	7.12e-05	0.000347	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	6.85e-05	0.000334	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—C3—amyotrophic lateral sclerosis	6.79e-05	0.000331	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CHAT—amyotrophic lateral sclerosis	6.63e-05	0.000323	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	6.62e-05	0.000323	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GSR—amyotrophic lateral sclerosis	6.57e-05	0.00032	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—PTGS2—amyotrophic lateral sclerosis	6.57e-05	0.00032	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—APOE—amyotrophic lateral sclerosis	6.32e-05	0.000308	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	6.27e-05	0.000306	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	6.2e-05	0.000302	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	6.05e-05	0.000295	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	5.98e-05	0.000292	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	5.88e-05	0.000287	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	5.6e-05	0.000273	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CHAT—amyotrophic lateral sclerosis	5.4e-05	0.000263	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	5.22e-05	0.000255	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	5.1e-05	0.000248	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	4.92e-05	0.00024	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	4.82e-05	0.000235	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	4.8e-05	0.000234	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	4.7e-05	0.000229	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	4.51e-05	0.00022	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	4.33e-05	0.000211	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.32e-05	0.000211	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	4.15e-05	0.000202	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	4.02e-05	0.000196	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—C3—amyotrophic lateral sclerosis	3.98e-05	0.000194	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.8e-05	0.000185	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	3.71e-05	0.000181	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.56e-05	0.000174	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	3.56e-05	0.000173	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.41e-05	0.000166	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	3.37e-05	0.000164	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.27e-05	0.00016	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.27e-05	0.000159	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	3.07e-05	0.000149	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.9e-05	0.000141	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—APOE—amyotrophic lateral sclerosis	2.69e-05	0.000131	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.67e-05	0.00013	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.58e-05	0.000126	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.36e-05	0.000115	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.23e-05	0.000109	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—APOE—amyotrophic lateral sclerosis	2.19e-05	0.000107	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2e-05	9.76e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.91e-05	9.32e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.85e-05	9e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.76e-05	8.57e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.51e-05	7.38e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.5e-05	7.32e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	1.45e-05	7.05e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	9.91e-06	4.83e-05	CbGpPWpGaD
